BioCentury
ARTICLE | Company News

Regulus reducing headcount by 60%

July 13, 2018 8:07 PM UTC

Regulus Therapeutics Inc. (NASDAQ:RGLS) reduced its headcount by an additional 60% and paused recruitment efforts for its RG-012 clinical program in Alport syndrome to save cash. In May 2017, the company reduced its headcount by 30% to 65 employees (see “Regulus Reducing Headcount by 30%”).

Regulus said it suspended the RG-012 program while it attempts to restructure a 2010 deal granting Sanofi (Euronext:SAN; NYSE:SNY) an option to develop and commercialize a number of microRNA therapeutics (see “Regulus, Sanofi Deal”)...

BCIQ Company Profiles

Regulus Therapeutics Inc.